The EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy
作者： Klaas Hoekman , Hester van Cruijsen , Giuseppe Giaccone
DOI: 10.1007/978-3-540-33177-3_39
关键词:
摘要: In tumor biology both the EGF(R) and VEGF(R) pathway are constitutively activated due to genetic abnormalities ongoing tumor-associated hypoxia. addition, pathways can be by anticancer therapies such as chemotherapy radiotherapy, which contributes resistance these treatments. Moreover, VEGF modulates EGFR signaling EGF induces activity. Therefore, logical targets for therapy, because of their parallel reciprocal activation, dual inhibition makes sense. this chapter we discuss possibilities integrated anti-angiogenesis therapy directed at two biological systems.
springer.com
sci-hub.st 参考文章(79)
Fortunato Ciardiello, Ferdinando De Vita, Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. Progress in drug research. ,vol. 63, pp. 93- 115 ,(2005) , 10.1007/3-7643-7414-4_5
R M Shaheen, S A Ahmad, W Liu, N Reinmuth, Y D Jung, W W Tseng, K E Drazan, C D Bucana, D J Hicklin, L M Ellis, Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors British Journal of Cancer. ,vol. 85, pp. 584- 589 ,(2001) , 10.1054/BJOC.2001.1936
Brian Fendly, Mien Chie Hung, Robert S. Kerbel, Alicia M. Viloria Petit, Patricia Rockwell, Neil Goldstein, Janusz Rak, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology. ,vol. 151, pp. 1523- 1530 ,(1997)
Paul Perrotte, Hiroki Kuniyasu, Beryl Y. Eve, Daniel J. Hicklin, Keiji Inoue, Colin P. N. Dinney, Robert Radinsky, Takashi Matsumoto, Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research. ,vol. 5, pp. 257- 265 ,(1999)
J. Drevs, M.A. Konerding, T. Wolloscheck, S.R. Wedge, A.J. Ryan, D.J. Ogilvie, N. Esser, The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis. ,vol. 7, pp. 347- 354 ,(2004) , 10.1007/S10456-005-1394-3
Makoto Sumitomo, Tomohiko Asano, Junichi Asakuma, Takako Asano, Akio Horiguchi, Masamichi Hayakawa, ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor–Extracellular Signal-Regulated Kinase Pathway Clinical Cancer Research. ,vol. 10, pp. 794- 801 ,(2004) , 10.1158/1078-0432.CCR-0948-03
Peter Carmeliet, VEGF as a key mediator of angiogenesis in cancer. Oncology. ,vol. 69, pp. 4- 10 ,(2005) , 10.1159/000088478
S. Yazici, S.J. Kim, J.E. Busby, J. He, P. Thaker, K. Yokoi, D. Fan, I.J. Fidler, Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice The Prostate. ,vol. 65, pp. 203- 215 ,(2005) , 10.1002/PROS.20283
Pasi A. Jänne, Sarada Gurubhagavatula, Beow Y. Yeap, Joan Lucca, Patricia Ostler, Arthur T. Skarin, Panos Fidias, Thomas J. Lynch, Bruce E. Johnson, Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study Lung Cancer. ,vol. 44, pp. 221- 230 ,(2004) , 10.1016/J.LUNGCAN.2003.12.014
Romàn Pérez-Soler, Phase II Clinical Trial Data with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer Clinical Lung Cancer. ,vol. 6, pp. S20- S23 ,(2004) , 10.3816/CLC.2004.S.010